MLTX250117C80000
- 0.35
- 0.000.00%
MoonLake Immunotherapeutics Newsroom
MoonLake Analyst Ratings
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Accolade (ACCD)
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $81
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62
MoonLake Immunotherapeutics Poised for Transformational Growth: Buy Rating Affirmed on Strategic Clinical Expansion and Strong Financial Position
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $77
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $65
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
MoonLake Immunotherapeutics' Promising Phase 3 Trials for PsA Treatment Drives Buy Rating
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Advancements and Strong Market Potential
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62